Exact Sciences Corporation maintained revenue guidance for the full year of 2024. For the period, the company has maintained its revenue guidance of $2.810 billion to $2.850 billion, assuming: screening revenue of $2.155 billion to $2.175 billion, and precision oncology revenue of $655 billion to $675 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.82 USD | -4.68% | -16.21% | -39.42% |
May. 24 | Sector Update: Health Care Stocks Advance Pre-Bell Friday | MT |
May. 24 | Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.42% | 8.68B | |
-3.57% | 3.2B | |
+14.27% | 2.71B | |
-18.81% | 2.04B | |
-24.39% | 1.64B | |
+36.26% | 1.43B | |
-7.86% | 718M | |
-26.94% | 538M | |
-8.35% | 287M | |
-12.14% | 170M |
- Stock Market
- Equities
- EXAS Stock
- News Exact Sciences Corporation
- Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024